Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. reports clinical, regulatory and financing developments as a clinical-stage biopharmaceutical company using CRISPR gene editing and other core technologies. Its recurring updates center on in vivo and ex vivo therapeutic approaches for genetically defined diseases, including lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and nexiguran ziclumeran, or nex-z, for ATTR amyloidosis with cardiomyopathy and polyneuropathy.
Company announcements also cover Phase 3 clinical data, FDA interactions, biologics license application activity, quarterly financial results, common stock offerings, equity incentive grants and investor conference participation. These updates reflect Intellia's progress from gene-editing research and clinical development toward regulatory and commercial planning for its lead programs.
Intellia Therapeutics (Nasdaq: NTLA) will report topline clinical data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema on April 27, 2026. This is described as the world's first Phase 3 readout for an in vivo CRISPR gene editing candidate.
The company will host a webcast at 8:00 a.m. ET on April 27, 2026 to discuss the topline results; a replay will be available for approximately 90 days.
Intellia Therapeutics (Nasdaq: NTLA) announced on April 1, 2026 it granted inducement awards to 13 new employees under its amended 2024 Inducement Plan. The awards comprised 67,150 RSUs vesting one-third annually over three years and were approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
All equity vesting is conditioned on continued service through vesting dates; awards were granted outside stockholder-approved plans pursuant to the inducement plan adopted by the board in June 2024.
Intellia Therapeutics (Nasdaq: NTLA) announced on March 6, 2026 that it granted inducement awards to six new employees under its 2024 Inducement Plan.
The awards were time-based restricted stock units totaling 16,500 shares, with one-third vesting annually over three years, granted March 1, 2026 and approved under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (Nasdaq: NTLA) presented four posters at AAAAI 2026 on lonvoguran ziclumeran (lonvo-z; NTLA-2002) for hereditary angioedema (HAE). A pooled Phase 1/2 cohort (n=32) given a one-time 50 mg dose showed durable plasma kallikrein reductions and a mean monthly attack rate ≤0.2 through up to three years.
Key readouts: 96% mean reduction in HAE attacks versus baseline, 31/32 (97%) attack-free and LTP-free at data cutoff, and 86% of 28 patients with >6 months follow-up attack-free and LTP-free for >6 months. A patient survey (n=100) highlighted ongoing treatment burden.
Intellia Therapeutics (Nasdaq: NTLA) announced the FDA has lifted the clinical hold on the IND for the MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z) in ATTR-CM, allowing enrollment to resume with enhanced safety measures.
Holds were originally placed on October 29, 2025 after a patient experienced Grade 4 liver transaminase elevations and increased bilirubin. Mitigations include intensified liver monitoring, short-term steroid guidance, new exclusion criteria (including ejection fraction <25% and recent cardiovascular instability), and exclusion for certain liver abnormalities. MAGNITUDE plans ~1,200 patients (2:1 randomization, single 55 mg infusion); MAGNITUDE-2 enrolls ~60 ATTRv-PN patients (1:1).
Intellia Therapeutics (Nasdaq: NTLA) reported Q4 and full-year 2025 results and program updates. Key items: HAELO Phase 3 topline data expected mid-2026, planned BLA submission in second half of 2026 and potential U.S. launch in first half of 2027 for lonvo-z. MAGNITUDE-2 enrollment to resume with completion expected in H2 2026; MAGNITUDE (ATTR-CM) remains on FDA clinical hold. Cash, cash equivalents and marketable securities were $605.1M at year-end, expected to fund operations into H2 2027.
Intellia Therapeutics (Nasdaq: NTLA) announced management will participate in three investor conferences in early March 2026, including TD Cowen (March 3), Leerink Global Healthcare (March 9) and Barclays Global Healthcare (March 10). The March 3 and March 9 fireside chats will be webcast live.
Webcasts and replays will be available on the company's Events and Presentations page at intelliatx.com; replays will remain available for approximately 90 days after each event.
Intellia Therapeutics (Nasdaq: NTLA) will host a conference call on February 26, 2026 at 8:00 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and business updates.
Investors may join via webcast or teleconference; a replay will be available for approximately 90 days on the company’s Events page.
Intellia Therapeutics (Nasdaq: NTLA) announced inducement equity awards granted on February 1, 2026 under its 2024 Inducement Plan.
The company awarded time-based restricted stock units totaling 30,600 shares to six new employees, vesting one-third annually over three years, subject to continued service. Awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) said the FDA has lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
The company plans to resume patient enrollment and dosing, has aligned with FDA on certain study modifications including enhanced liver safety monitoring, and increased MAGNITUDE-2 target enrollment from ~50 to ~60 patients. Engagement with FDA remains ongoing for the related MAGNITUDE Phase 3 trial in transthyretin amyloidosis with cardiomyopathy (ATTR-CM); an update will follow after alignment on the path forward.